| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Biao Xu | |
| Fu Chen | |||
| Qing-Qing Zhu | |||
| Xin-Lin Zhang | |||
| Jian-An Huang | |||
| Xue-Ling Li | |||
| Yu-Han Chen | |||
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies | Q26765047 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Association of Cardiometabolic Multimorbidity With Mortality | Q28606934 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus | Q30245104 | ||
| Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus | Q30249371 | ||
| Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. | Q30903369 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses | Q33372680 | ||
| Long-term effects of intensive glucose lowering on cardiovascular outcomes | Q33851861 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin | Q36431654 | ||
| Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes | Q38218644 | ||
| Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot | Q38376619 | ||
| Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy | Q38502148 | ||
| Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. | Q38615440 | ||
| Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data. | Q38665387 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials | Q38793234 | ||
| Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus | Q38827756 | ||
| Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. | Q38912082 | ||
| Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms | Q39318765 | ||
| Novel Diabetes Drugs and the Cardiovascular Specialist | Q39330831 | ||
| Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes | Q41605742 | ||
| Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study | Q41745784 | ||
| Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? | Q42376494 | ||
| Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis | Q43471039 | ||
| 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q44265041 | ||
| Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies | Q44438668 | ||
| Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes | Q45190512 | ||
| Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years | Q47871792 | ||
| Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014. | Q48138412 | ||
| Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions | Q48350642 | ||
| Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study | Q48360915 | ||
| Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real W | Q50042476 | ||
| SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. | Q50066726 | ||
| Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. | Q50089120 | ||
| Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor | Q50955035 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. | Q51832630 | ||
| Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
| 2013 ESC guidelines on the management of stable coronary artery disease | Q57243329 | ||
| Thiazolidinediones and Heart Failure: A teleo-analysis | Q57413498 | ||
| Assessing the cardiovascular safety of diabetes therapies | Q81950632 | ||
| Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial | Q88117871 | ||
| SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System | Q88579083 | ||
| P433 | issue | 2 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P577 | publication date | 2018-01-20 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis | |
| P478 | volume | 7 |
| Q90732416 | Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials |
| Q92805657 | Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes |
| Q92355579 | Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review |
| Q91725845 | Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis |
| Q58576729 | Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol |
| Q88969119 | Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement |
| Q92108931 | Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure |
| Q57026285 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q56979722 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q92435311 | Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2 |
| Q92835456 | Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes |
| Q92703271 | SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects |
| Q59330606 | Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study |
| Q90470148 | Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing |
| Q64916602 | The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. |
| Q92992644 | Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study |
| Q92608090 | What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer? |
Search more.